Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic VEGF Levels with Ranibizumab vs Aflibercept in DME
NCT02878681Phase 4Withdrawn
- Sponsor
- Novartis
- Start
- Sep 2016
- Primary completion
- Sep 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 4 trial of ranibizumab in diabetic macular edema (DME), sponsored by Novartis. Planned start Sep 2016; status: withdrawn.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02878681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02878681.